Prolacta Bioscience produces human milk–based products and formulas tailored for premature and critically ill infants in neonatal intensive care. The company operates what the article calls the first and only pharmaceutical-grade manufacturing facility for processing human breast milk. Prolacta recently moved from City of Industry into a 40,300-square-foot LEED Gold headquarters in Duarte. Its core product focus is on human milk–derived nutrition rather than standard infant formulas. The company has an established funding history, having raised $69.1 million across six rounds through December 2016, according to Crunchbase. In the most recent reported filing it secured additional capital via a securities sale. Prolacta Bioscience is the nation's leading provider of human milk-based neonatal nutritional products and operates a pharmaceutical-grade manufacturing facility for donor human milk. Its products are used as part of an exclusive human milk diet for extremely premature infants (500–1,250g at birth) and are clinically proven to improve health outcomes and reduce hospital costs compared with cow milk-based fortifiers or preterm formula. The company is described in the release as already substantially profitable while in the early stages of its growth trajectory. Proceeds from the financing will be used to expand Prolacta's commercial presence in European markets and to support clinical trials of its human milk-based products for additional indications both in and out of the NICU. Prolacta also plans to accelerate a therapeutic development program to evaluate human milk oligosaccharides (HMOs) to treat microbiome-related diseases. The company emphasizes product quality and safety in neonatal nutrition and is headquartered in City of Industry, California. Prolacta is a Monrovia, California-based company that develops human milk-based fortifiers used to feed and treat premature infants. Its products are made from human breast milk and aim to avoid necrotizing enterocolitis associated with cow-based fortifiers. The company announced it closed a Series D round led by Health Evolution Partners. Prolacta did not publicly disclose the round size, but a regulatory filing indicates the equity funding was worth $15.0M. As part of the investment, Health Evolution Partners partners Joshua Saipe and Ned Brown joined Prolacta’s board of directors. Prolacta Bioscience is a Monrovia-based company developing a human milk fortifier made from human milk for use in neonatal intensive care units. On May 23, 2007 the firm announced it raised $12M in a funding round. The financing was led by Alta Partners and included DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, Draper Associates L.P., and other investors. Alison de Bord of Alta Partners joined Prolacta's board in conjunction with the round. The article does not disclose operating metrics, terms of the financing, or specific uses for the proceeds. Coverage focuses on the product and investor participation. Prolacta Bioscience is a Monrovia-based company developing specialty formulations of human milk designed for premature and critically ill infants. The firm raised $5M in a Series B prime financing round. Investors in the round included Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, and the Gideon Hixon Fund. Existing investors DFJ Frontier, Draper Richards, and Draper Associates also participated. The company said the round included several high-profile angel investors. The funding was reported on October 4, 2006.

Total raised

$76M

Funding rounds

5

Latest round

Equity

Latest activity

May 2018